Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.

The results of the responder analysis at 90 days are shown in Figure S1 , and include the proportion of patients treated with empagliflozin versus placebo that had a clinically significant deterioration (≥5 point decline in KCCQ-TSS [8.0% versus 11.7%; odds ratio, 0.67 [95% CI, 0.35–1.30; P =0.24); and at least small (87.5% versus 82.4%), moderate (83.1% versus 76.3%), or large (70.4% versus 65.5%) improvements in KCCQ-TSS (corresponding odds ratio [95% CI]: 1.49 [95% CI, 0.84–2.64], P =0.17; 1.52 [95% CI, 0.93–2.50], P =0.10; 1.22 [95% CI, 0.78–1.89], P =0.38); these results did not reach statistical significance.

also in 111,027 other papers